HOWL vs. REPL, DMAC, BNTC, LXEO, IMAB, ALT, DBVT, EDIT, ALTS, and ANNX
Should you be buying Werewolf Therapeutics stock or one of its competitors? The main competitors of Werewolf Therapeutics include Replimune Group (REPL), DiaMedica Therapeutics (DMAC), Benitec Biopharma (BNTC), Lexeo Therapeutics (LXEO), I-Mab (IMAB), Altimmune (ALT), DBV Technologies (DBVT), Editas Medicine (EDIT), ALT5 Sigma (ALTS), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry.
Werewolf Therapeutics vs. Its Competitors
Replimune Group (NASDAQ:REPL) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.
Replimune Group presently has a consensus price target of $6.50, suggesting a potential upside of 48.91%. Werewolf Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 398.44%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Werewolf Therapeutics is more favorable than Replimune Group.
Replimune Group's return on equity of -69.34% beat Werewolf Therapeutics' return on equity.
Werewolf Therapeutics has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.
92.5% of Replimune Group shares are held by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are held by institutional investors. 5.2% of Replimune Group shares are held by insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Replimune Group has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.
In the previous week, Werewolf Therapeutics had 3 more articles in the media than Replimune Group. MarketBeat recorded 5 mentions for Werewolf Therapeutics and 2 mentions for Replimune Group. Replimune Group's average media sentiment score of 0.95 beat Werewolf Therapeutics' score of 0.50 indicating that Replimune Group is being referred to more favorably in the media.
Summary
Werewolf Therapeutics beats Replimune Group on 10 of the 14 factors compared between the two stocks.
Get Werewolf Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HOWL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Werewolf Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:HOWL) was last updated on 10/14/2025 by MarketBeat.com Staff
